TCT

SAN FRANCISCO — Analyses continue to show a long-term mortality risk associated with paclitaxel-coated devices in patients with peripheral artery disease, but investigators are no closer to determining a cause, according to members of a panel convened at TCT 2019.

SAN FRANCISCO — Guidance with OCT led to a lower occurrence of significant angina or the composite of MACE compared with guidance with fractional flow reserve in patients with angiographically intermediate coronary lesions, according to 13-month data from the FORZA trial presented at TCT 2019.

SAN FRANCISCO — A cobalt-chromium drug-eluting stent was noninferior to a stainless steel DES in patients with ACS who were undergoing PCI, according to 18-month results from the BIODEGRADE trial presented at TCT 2019.

SAN FRANCISCO — Orbital and rotational atherectomy conferred similar outcomes in patients with calcified CAD who underwent PCI, according to the results of a retrospective cohort study presented at TCT 2019.

Healio was on-site at TCT 2019, which offered a number of late-breaking presentations on innovations in the treatment of structural heart disease. Below are some of the highlights.

SAN FRANCISCO — Among patients who underwent PCI for long lesions, IVUS-based guidance was associated with better outcomes than angiography-based guidance at 5 years, according to new data from the IVUS-XPL trial presented at TCT 2019.

SAN FRANCISCO — Compared with patients assigned surgery, those assigned transcatheter aortic valve replacement had a better Kansas City Cardiomyopathy Questionnaire-Overall Summary, or KCCQ-OS, score at 1 month, 6 months and 12 months, according to new data from the PARTNER 3 trial presented at TCT 2019.

As drug-eluting stent technology has evolved, stent thrombosis has become less of a risk and the standard recommendation of 1 year of dual antiplatelet therapy after PCI is being challenged, especially for patients at high bleeding risk.

SAN FRANCISCO — Among patients with three-vessel disease who underwent PCI, achievement of a quantitative flow ratio of at least 0.91 in all treated vessels was associated with improved vessel-related outcomes, according to findings presented at TCT 2019.

SAN FRANCISCO — An intravascular lithotripsy device used for vessel preparation for stenting in patients with severely calcified coronary lesions was safe and effective, according to results from the DISRUPT CAD II study presented at TCT 2019.